LAKE OSWEGO, Ore., July 16 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation , medical diagnostic tests manufacturer for the rapid detection of antibodies to the human immunodeficiency virus (HIV) announced today that Roger I. Gale, Chairman and Chief Executive Officer and Richard D. Brounstein, Executive Vice President, will speak to the investment community at CapStone Investments’ First Annual Small-Cap Investor Conference in Milwaukee, Wisconsin. The conference will be archived for on-demand webcasting after the conference has concluded.
Mr. Gale and Mr. Brounstein will provide an update regarding the Company’s recent activities at CapStone Investments’ First Annual Small-Cap Investor Conference in Milwaukee, Wisconsin at approximately 2:30pm CDT on Tuesday, July 17, 2007. The presentation will be publicly available at http://www.capstoneinvestments.com/page.asp?itemid=62 after the conference concludes on Tuesday
About Calypte Biomedical:
Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the AwareTM HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Company Contact: Richard Brounstein, Executive Vice President (971) 204-0282 email: rbrounstein@calypte.com Investor Relations Contact: Tim Clemensen, Rubenstein Investor Relations Phone: (212) 843-9337 email: tclemensen@rubensteinir.com
Calypte Biomedical Corporation
CONTACT: Company: Richard Brounstein, Executive Vice President, +1-971-204-0282, rbrounstein@calypte.com, or Investor Relations: Tim Clemensen,Rubenstein Investor Relations, +1-212-843-9337, tclemensen@rubensteinir.com
Web site: http://www.calypte.com/
